Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors
- 31 March 1993
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 44 (4-6), 557-563
- https://doi.org/10.1016/0960-0760(93)90259-y
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The efficacy and safety of terazosin for the treatment of symptomatic BPHThe Prostate, 1991
- Histological localization of estrogen receptors in normal and diseased human prostates by immunocytochemistryThe Prostate, 1990
- Selective inhibition of androstenedione‐induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1‐methyl‐androsta‐1,4‐diene‐3,17‐dione (1‐methyl‐ADD)The Prostate, 1989
- Estrogen and Progestin Receptors and Aromatase Activity in Rhesus Monkey Prostate*Endocrinology, 1988
- Immunocytochemical localization of estrogen receptors in spontaneous and experimentally induced canine benign prostatic hyperplasiaThe Prostate, 1987
- Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal.JCI Insight, 1983
- Effects of Cyproterone Acetate on Experimentally Induced Canine Prostatic HyperplasiaUrologia Internationalis, 1980
- Comparison of spontaneous and experimentally induced canine prostatic hyperplasia.JCI Insight, 1979
- The induction of prostatic hypertrophy in the dog with androstanediol.JCI Insight, 1976
- THE QUESTION OF CASTRATION FOR ENLARGED PROSTATEAnnals of Surgery, 1896